* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download PD Dr. Tobias CANTZ
Survey
Document related concepts
Cytokinesis wikipedia , lookup
Cell growth wikipedia , lookup
Extracellular matrix wikipedia , lookup
Tissue engineering wikipedia , lookup
Cell encapsulation wikipedia , lookup
Cell culture wikipedia , lookup
Organ-on-a-chip wikipedia , lookup
List of types of proteins wikipedia , lookup
Hematopoietic stem cell wikipedia , lookup
Stem-cell therapy wikipedia , lookup
Somatic cell nuclear transfer wikipedia , lookup
Transcript
CURRICULUM VITAE Tobias Cantz, MD REBIRTH cluster of Excellence Hannover Medical School and Max Planck Institut Münster Translational Hepatology and Stem Cell Biology Carl-Neuberg-Str. 1 30625 Hanover, Germany www.rebirth-hannover.de/cantz e-mail: [email protected] Academic Curriculum: 1993 - 2000 Studies of Medicine, Ruprecht Karls University, Heidelberg, Germany 1997 - 2000 Doctorate at German Cancer Research Center (DKFZ) Heidelberg, Germany. Dept. of Tumorbiochemistry (Prof. D. Keppler) 2000 - 2004 Physician and staff scientist Dept. of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Germany (Prof. M. Manns) 2004 - 2008 Staff scientist, Max Planck Institute for Molecular Biomedicine, Muenster, Germany (Hans R. Schöler) 2008 - present Head of the Research Group ‘Translational Hepatology and Stem Cell Biology’ in the Cluster of Excellence REBIRTH, Hannover Medical School, Germany Scientific Awards: 2007 Coordinator of www.zellux.net (web-based teaching material for high school pupils on ethics and therapeutic perspectives of human embryonic stem cells) 2011 Pro Scientia Prize of the Eckhart-Buddecke-Foundation 2013 Founding Member of the German Stem Cell network (www.gscn.org) Research Interests: Stem cell biology in hepatic differentiation and regeneration, generation of induced pluripotent stem cells (iPS cells), molecular mechanisms underlying epigenetic reprogramming / trans-programming, stem cell-based liver disease models, ethical aspects of embryonic stem cell and iPS cell research. Selected Publications: Eggenschwiler R, Loya K, Wu G, Sharma AD, Sgodda M, Zychlinski D, Herr C, Steinemann D, Teckman J, Bals R, Ott M, Schambach A, Schöler HR, Cantz T (2013). Sustained knockdown of a diseasecausing gene in patient specific induced pluripotent stem cells using lentiviral vector based gene therapy. Stem Cells Translat Med. 2(9):641-54. Pfaff N & Cantz T (2013). From Skin to Blood: A New Member Joins the iClub. Cell Stem Cell. 13(2):131-3. Sgodda M, Möbus S, Hoepfner J, Sharma AD, Schambach A, Greber B, Ott M, Cantz T (2013). Improved Hepatic Differentiation Strategies for Human Induced Pluripotent Stem Cells. Curr Mol Medicine, 13(5):842-55. Pfaff N, Fiedler J, Holzmann A, Schambach A, Moritz T, Cantz T*, Thum T* (2011). MiRNA screening reveals a new miRNA family stimulating iPS cell generation via regulation of Meox2. EMBOreports 12(11):1153-59 (*corresponding authors) Wu G, Liu N, Rittelmeyer I, Sharma AD, Sgodda M, Zaehres H, Bleidissel M, Greber B, Gentile L, Han DW, Rudolph C, Steinemann D, Schambach A, Ott M, Schöler HR, Cantz T (2011). Generation of Healthy Mice from Gene-Corrected Disease-Specific Induced Pluripotent Stem Cells. PLoS Biol 9(7): e1001099 2 Abstract: Direct reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) is a promising approach for the derivation of disease-specific iPSCs. In the clinical setting, patient-specific iPSCs must undergo repair prior to autologous cell transplantation if the underlying condition was caused by a genetic disorder and long-term functional capabilities of the gene-corrected cells needs to be ensured. Aiming at robust reprogramming protocols we investigated the effects of all 16 reprogramming factor stoichiometries and evaluated a versatile polycistronic reprogramming vector, expressing all four factors (Oct4, Sox2, Klf4, and c-Myc). Furthermore, we identifed several microRNAs, whose modulation improved the efficacy of iPS cell generation. Moreover, we evaluated a cytokine and small molecule based protocol for direct differentiation of human embryonic stem cells (hESC) and hiPS cells into hepatic cells that could be visualized and selected by a lentiviral albumin-GFP/Neo construct. Functional characterization of these cells allowed the recapitulation of the disease phenotype for further studies of underlying molecular mechanisms of the respective disease. Aiming at a sustained knock-down of a disease causing gene in iPSCs and their differentiated derivatives, we investigated a novel approach for the expression of a therapeutic shRNA in α-1-antitrypsin deficiency (A1AT)-specific iPSC using third generation lentiviral vectors. With this novel strategy, we were able to achieve a significant reduction in the expression of the mutated PiZ-A1At variant in transduced and differentiated disease specific iPSC from a murine model and from one individual suffering from severe α-1-antitrypsin deficiency-associated liver disease. With respect to stem cell-based therapies, often postulated hypotheses suggested that more proliferative fetal or stem cell-derived hepatic cells perform better as hepatic cell transplants than adult hepatocytes and, therefore, should be considered as preferential cell source. In a xenograftaccepting mouse strain, which serves as competitive liver repopulation model, we could not confirm such hypotheses, but our results suggested that the maturity of transplanted cells has a major effect of engraftment and repopulation efficiencies. Therefore, we aim at further improvements in the hepatic differentiation protocols of human pluripotent stem cells that eventually yield in transplantable cells exhibiting long-term repopulation capabilities in xeno-graft accepting animals.